Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16020085 | 1.00 | GPBAR1 (0.33) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16020088 | 1.00 | GPBAR1 (0.33) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16020090 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16010120 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16010616 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16020124 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL18213645 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16010142 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16010571 | 0.86 | GPBAR1 (0.44) | GPBAR1LMNACYP3A4MAPK1SHBG | |
| SCHEMBL16020078 | 0.82 | GPBAR1 (0.32) | GPBAR1LMNACYP3A4MAPK1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2016-11-10 | — | — | US | disclosed |
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | GPBAR1 103/4885LMNA 4611/4885CYP3A4 570/4885 |
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | GPBAR1 103/4885LMNA 4611/4885CYP3A4 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.